开云app官网登录入口网页版-官方正版

#RRMM#

2篇内容 | 882人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2223937, encodeId=fa95222393ef7, content=<a href='/topic/show?id=edba4069ec' target=_blank style='color:#2F92EE;'>#CAR-T治疗#</a> <a href='/topic/show?id=0b2110210e2e' target=_blank style='color:#2F92EE;'>#髓外病变#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【AJH】曹江/徐开林/郑骏年教授牵头，BCMA CAR-T治疗RRMM伴髓外病变的临床结局, objectType=article, longId=841728, objectId=1646841e283a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240903/1725341171858_8538692.jpg, objectUrl=/article/show_article.do?id=1646841e283a, replyNumber=0, likeNumber=24, createdTime=2024-09-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1646841e283a, moduleTitle=【AJH】曹江/徐开林/郑骏年教授牵头，BCMA CAR-T治疗RRMM伴髓外病变的临床结局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1646841e283a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2223938, encodeId=b4ad2223938e0, content=<a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a> <a href='/topic/show?id=7dfd118694e3' target=_blank style='color:#2F92EE;'>#CAR-HEMATOTOX评分#</a>, objectTitle=【BJH】CAR-HEMATOTOX评分可预测双抗治疗RRMM的感染风险和生存结局, objectType=article, longId=841729, objectId=cee1841e2910, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240801/1722498027751_8538692.jpg, objectUrl=/article/show_article.do?id=cee1841e2910, replyNumber=0, likeNumber=36, createdTime=2024-09-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cee1841e2910, moduleTitle=【BJH】CAR-HEMATOTOX评分可预测双抗治疗RRMM的感染风险和生存结局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cee1841e2910)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2223454, encodeId=71f3222345441, content=<a href='/topic/show?id=168a3e464ad' target=_blank style='color:#2F92EE;'>#双抗治疗#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【BCJ】RRMM在双抗治疗缓解后停药，仍可维持缓解, objectType=article, longId=841283, objectId=aa4b84128306, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240826/1724638905319_8538692.png, objectUrl=/article/show_article.do?id=aa4b84128306, replyNumber=0, likeNumber=23, createdTime=2024-09-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=aa4b84128306, moduleTitle=【BCJ】RRMM在双抗治疗缓解后停药，仍可维持缓解, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aa4b84128306)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2223050, encodeId=0c562223050ee, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a> <a href='/topic/show?id=6b67112e51a8' target=_blank style='color:#2F92EE;'>#特立妥单抗#</a>, objectTitle=【Blood】特立妥单抗用于接受过BCMA治疗的RRMM的疗效和安全性, objectType=article, longId=840888, objectId=857c8408882d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240718/1721281386020_92910.jpg, objectUrl=/article/show_article.do?id=857c8408882d, replyNumber=0, likeNumber=27, createdTime=2024-08-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=857c8408882d, moduleTitle=【Blood】特立妥单抗用于接受过BCMA治疗的RRMM的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=857c8408882d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2221312, encodeId=95c12221312c6, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【柳叶刀血液学】BCMA/GPRC5D双特异性CAR-T细胞治疗RRMM的I期研究, objectType=article, longId=839469, objectId=6a6e8394699b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240711/1720669414779_5579292.png, objectUrl=/article/show_article.do?id=6a6e8394699b, replyNumber=0, likeNumber=63, createdTime=2024-08-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6a6e8394699b, moduleTitle=【柳叶刀血液学】BCMA/GPRC5D双特异性CAR-T细胞治疗RRMM的I期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6a6e8394699b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2204164, encodeId=4c03220416472, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【Blood Adv】首次对比CAR-T和双抗：治疗三重难治RRMM的回顾性研究, objectType=article, longId=825326, objectId=f186825326d2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240511/1715434220624_5579292.jpg, objectUrl=/article/show_article.do?id=f186825326d2, replyNumber=0, likeNumber=86, createdTime=2024-05-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f186825326d2, moduleTitle=【Blood Adv】首次对比CAR-T和双抗：治疗三重难治RRMM的回顾性研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f186825326d2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200833, encodeId=b1902200833d1, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【Nat Commun】BCMA和CD19双特异性CAR-T治疗RRMM的中国I/II期研究, objectType=article, longId=823394, objectId=bf0882339437, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PAJM2K5.jpg, objectUrl=/article/show_article.do?id=bf0882339437, replyNumber=0, likeNumber=75, createdTime=2024-04-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bf0882339437, moduleTitle=【Nat Commun】BCMA和CD19双特异性CAR-T治疗RRMM的中国I/II期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bf0882339437)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2193018, encodeId=64df2193018f0, content=<a href='/topic/show?id=e69f11185836' target=_blank style='color:#2F92EE;'>#BCMA CAR-T#</a> <a href='/topic/show?id=c717425931e' target=_blank style='color:#2F92EE;'>#复发难治性多发性骨髓瘤#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a> <a href='/topic/show?id=26651122455a' target=_blank style='color:#2F92EE;'>#MyCARe#</a>, objectTitle=【JCO】BCMA CAR-T治疗RRMM的MyCARe预后模型, objectType=article, longId=816973, objectId=b0f28169e3d2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=b0f28169e3d2, replyNumber=0, likeNumber=77, createdTime=2024-03-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b0f28169e3d2, moduleTitle=【JCO】BCMA CAR-T治疗RRMM的MyCARe预后模型, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b0f28169e3d2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2192543, encodeId=170e2192543c2, content=<a href='/topic/show?id=e69f11185836' target=_blank style='color:#2F92EE;'>#BCMA CAR-T#</a> <a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=【Blood Adv】多发性骨髓瘤BCMA CAR-T复发后挽救治疗（含抗BCMA再治疗）的结局, objectType=article, longId=816721, objectId=27d2816e211a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-at-work-PGMH47J.jpg, objectUrl=/article/show_article.do?id=27d2816e211a, replyNumber=0, likeNumber=64, createdTime=2024-03-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=27d2816e211a, moduleTitle=【Blood Adv】多发性骨髓瘤BCMA CAR-T复发后挽救治疗（含抗BCMA再治疗）的结局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=27d2816e211a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2177467, encodeId=b3f921e7467fc, content=<a href='/topic/show?id=a04e4135027' target=_blank style='color:#2F92EE;'>#地塞米松#</a> <a href='/topic/show?id=c34d64e47d1' target=_blank style='color:#2F92EE;'>#泊马度胺#</a> <a href='/topic/show?id=7f389396e27' target=_blank style='color:#2F92EE;'>#达雷妥尤单抗#</a> <a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>, objectTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, objectType=article, longId=806561, objectId=31fe806561d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-filling-form-U2MAYRK.jpg, objectUrl=/article/show_article.do?id=31fe806561d8, replyNumber=0, likeNumber=88, createdTime=2023-12-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=31fe806561d8, moduleTitle=2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=31fe806561d8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2126335, encodeId=bd29212633551, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a><a href='/topic/show?id=6dbf10589ea2' target=_blank style='color:#2F92EE;'>#CD3/BCMA双抗#</a><a href='/topic/show?id=8ecd10589883' target=_blank style='color:#2F92EE;'>#Elranatamab#</a>治疗<a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a><a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布, objectType=article, longId=751741, objectId=209ee51741ba, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/bea5c122810c404a8ba7de429c8571e3.jpg, objectUrl=/article/show_article.do?id=209ee51741ba, replyNumber=0, likeNumber=148, createdTime=2023-04-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=香港, moduleDTOList=[ModuleDTO(moduleId=209ee51741ba, moduleTitle=ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=209ee51741ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2106183, encodeId=9205210618383, content=<a href='/topic/show?id=833732e80d' target=_blank style='color:#2F92EE;'>#BCMA#</a> <a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>对<a href='/topic/show?id=c0f04250423' target=_blank style='color:#2F92EE;'>#复发/难治性多发性骨髓瘤#</a> (<a href='/topic/show?id=6ec61050e7b0' target=_blank style='color:#2F92EE;'>#RRMM#</a>) 的ORR高达100%，<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=ASH 2022：BCMA CAR-T细胞治疗对复发/难治性多发性骨髓瘤 (RRMM) 的ORR高达100%, objectType=article, longId=751775, objectId=7a43e517755a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/a9bcb1349b95450e89ed095619943365.jpg, objectUrl=/article/show_article.do?id=7a43e517755a, replyNumber=0, likeNumber=0, createdTime=2022-12-15, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7a43e517755a, moduleTitle=ASH 2022：BCMA CAR-T细胞治疗对复发/难治性多发性骨髓瘤 (RRMM) 的ORR高达100%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7a43e517755a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 侠胆医心

BCMA CAR-T细胞治疗对复发/难治性多发性骨髓瘤 (RRMM) 的ORR高达100%，多发性骨髓瘤

2022-12-15发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#CAR-T治疗# #髓外病变# #RRMM#

【AJH】曹江/徐开林/郑骏年教授牵头，BCMA CAR-T治疗RRMM伴髓外病变的临床结局

2024-09-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#RRMM# #CAR-HEMATOTOX评分#

【BJH】CAR-HEMATOTOX评分可预测双抗治疗RRMM的感染风险和生存结局

2024-09-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#双抗治疗# #RRMM#

【BCJ】RRMM在双抗治疗缓解后停药，仍可维持缓解

2024-09-01发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#BCMA# #RRMM# #特立妥单抗#

【Blood】特立妥单抗用于接受过BCMA治疗的RRMM的疗效和安全性

2024-08-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #CAR-T细胞治疗# #RRMM#

【柳叶刀血液学】BCMA/GPRC5D双特异性CAR-T细胞治疗RRMM的I期研究

2024-08-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #CAR-T# #RRMM#

【Blood Adv】首次对比CAR-T和双抗：治疗三重难治RRMM的回顾性研究

2024-05-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #CAR-T# #BCMA# #RRMM#

【Nat Commun】BCMA和CD19双特异性CAR-T治疗RRMM的中国I/II期研究

2024-04-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#BCMA CAR-T# #复发难治性多发性骨髓瘤# #RRMM# #MyCARe#

【JCO】BCMA CAR-T治疗RRMM的MyCARe预后模型

2024-03-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#BCMA CAR-T# #多发性骨髓瘤# #RRMM#

【Blood Adv】多发性骨髓瘤BCMA CAR-T复发后挽救治疗（含抗BCMA再治疗）的结局

2024-03-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#地塞米松# #泊马度胺# #达雷妥尤单抗# #RRMM#

2023 ASH真实世界研究：泊马度胺、达雷妥尤单抗、地塞米松联合方案（DPd）较DKd延长RRMM患者OS

2023-12-27发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#辉瑞##CD3/BCMA双抗##Elranatamab#治疗#RRMM##多发性骨髓瘤#

ASH 2022：辉瑞CD3/BCMA双抗Elranatamab治疗RRMM结果公布

2023-04-16发表于香港

侠胆医心 (审核中...)

前往app查看评论内容

#BCMA# #CAR-T细胞治疗#对#复发/难治性多发性骨髓瘤# (#RRMM#) 的ORR高达100%，#多发性骨髓瘤#

ASH 2022：BCMA CAR-T细胞治疗对复发/难治性多发性骨髓瘤 (RRMM) 的ORR高达100%

2022-12-15发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务